Agenus Inc (AGEN)vsRevolution Medicines Inc (RVMD)
AGEN
Agenus Inc
$3.23
-4.86%
HEALTHCARE · Cap: $144.92M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Agenus Inc generates 16594% more annual revenue ($123.87M vs $742,000). AGEN leads profitability with a 52.2% profit margin vs 0.0%. AGEN earns a higher WallStSmart Score of 58/100 (C).
AGEN
Buy58
out of 100
Grade: C
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 44.6%
Revenue surging 40.2% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -1279.0% — below average capital efficiency
Negative free cash flow — burning cash
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AGEN
The strongest argument for AGEN centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 52.2% and operating margin at 44.6%. Revenue growth of 40.2% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : AGEN
The primary concerns for AGEN are EPS Growth, Market Cap, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
AGEN profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
AGEN carries more volatility with a beta of 1.60 — expect wider price swings.
AGEN is growing revenue faster at 40.2% — sustainability is the question.
AGEN generates stronger free cash flow (-36M), providing more financial flexibility.
Bottom Line
AGEN scores higher overall (58/100 vs 24/100), backed by strong 52.2% margins and 40.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agenus Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?